Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Complera / Eviplera (FTC / rilpivirine / TDF by Year
Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — Europe sales ($M) ($M)
Gilead Sciences Complera / Eviplera (FTC / rilpivirine / TDF: $70M in FY2023, down 38.1% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) — Europe sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 70 | -38.1% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 113 | -20.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 142 | -10.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 159 | -25.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 214 | -34.6% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 327 | -35.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 503 | -13.3% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 580 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Complera / Eviplera (FTC / rilpivirine / TDF ($M), annual FY2016–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-complera-eu
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.